JP2001522235A - ターゲッティング分子を用いた免疫応答の増強 - Google Patents
ターゲッティング分子を用いた免疫応答の増強Info
- Publication number
- JP2001522235A JP2001522235A JP54098998A JP54098998A JP2001522235A JP 2001522235 A JP2001522235 A JP 2001522235A JP 54098998 A JP54098998 A JP 54098998A JP 54098998 A JP54098998 A JP 54098998A JP 2001522235 A JP2001522235 A JP 2001522235A
- Authority
- JP
- Japan
- Prior art keywords
- hig
- pci
- mice
- antigen
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/008—Leishmania antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/05—Actinobacteria, e.g. Actinomyces, Streptomyces, Nocardia, Bifidobacterium, Gardnerella, Corynebacterium; Propionibacterium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/385—Haptens or antigens, bound to carriers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
- C07K14/34—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Corynebacterium (G)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
- C07K14/43536—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms
- C07K14/4355—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from cestodes
- C07K14/43554—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from worms from cestodes from Taenia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
- C07K14/445—Plasmodium
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70521—CD28, CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.抗原に対する免疫応答を誘起するために使用するDNA分子であって、 ターゲッティング分子をコードする第1の配列と、前記抗原またはそのエピ トープをコードする第2の配列と、場合により、前記DNA分子によりコードされ る産物の二量体化または多量体化を促進するポリペプチドをコードする第3の 配列とを含んでなるDNA分子。 2.前記第2の配列によりコードされる抗原またはそのエピトープが、前記DNA分 子によりコードされる産物の二量体化または多量体化を促進するポリペプチド であって、かつ前記第3の配列が存在しない、請求項1に記載のDNA分子。 3.前記第3の配列が存在する、請求項1に記載のDNA分子。 4.前記第1の配列によりコードされるターゲッティング分子が、リンパ球様細 胞、リンパ系部位、または抗原提示細胞を標的とするリガンドである、請求項 1〜3のいずれか1項に記載のDNA分子。 5.前記第1の配列によりコードされるターゲッティング分子が、CTLA4、L-セレ クチン、CD40L,OX40、CD28、および抗原提示細胞上の受容体に対する抗体か らなる群より選ばれる、請求項1〜4のいずれか1項に記載のDNA分子。 6.前記第1の配列によりコードされるターゲッティング分子がCTLA4である、 請求項1〜5のいずれか1項に記載のDNA分子。 7.請求項1〜6のいずれか1項に記載のDNA分子によりコードされるポリペプ チド。 8.請求項1〜6のいずれか1項に記載のDNA分子を含んでなるベクター。 9.動物中で免疫応答を誘起するために使用する組成物であって、 請求項1〜6のいずれか1項に記載のDNA分子または請求項8に記載のベク ターと、許容しうる希釈剤または賦形剤とを含んでなる組成物。 10.動物中で免疫応答を誘起するために使用する組成物であって、 請求項7に記載のポリペプチドと、許容しうる希釈剤または賦形剤とを含ん でなる組成物。 11.動物中で免疫応答を誘起させる方法であって、 請求項9または10に記載の組成物を動物に投与するステップを含む方法。 12.個体中で抗原に対する免疫応答を偏向させる方法であって、 CTLA4をコードする第1の配列と、前記抗原またはそのエピトープをコードす る第2の配列と、場合により、前記DNA分子によりコードされる産物の二量体化 または多量体化を促進するポリペプチドをコードする第3の配列とを含んでな るDNA分子を前記個体に投与するステップを含む方法。 13.前記第2の配列によりコードされる抗原またはそのエピトープが、前記DNA 分子によりコードされる産物の二量体化または多量体化を促進するポリペプチ ドであって、かつ前記第3の配列が存在しない、請求項12に記載の方法。 14.前記第3の配列が存在する、請求項12に記載の方法。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AUPO5891A AUPO589197A0 (en) | 1997-03-27 | 1997-03-27 | Enhancement of immune response using targeting molecules |
AU5891 | 1998-02-13 | ||
AUPP1830A AUPP183098A0 (en) | 1998-02-13 | 1998-02-13 | Enhancement of immune response using targeting molecules |
PCT/AU1998/000208 WO1998044129A1 (en) | 1997-03-27 | 1998-03-26 | Enhancement of immune response using targeting molecules |
AU1830 | 1999-07-27 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2001522235A true JP2001522235A (ja) | 2001-11-13 |
JP4382163B2 JP4382163B2 (ja) | 2009-12-09 |
Family
ID=25645385
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP54098998A Expired - Lifetime JP4382163B2 (ja) | 1997-03-27 | 1998-03-26 | ターゲッティング分子を用いた免疫応答の増強 |
Country Status (8)
Country | Link |
---|---|
US (2) | US7423016B2 (ja) |
EP (1) | EP0972054B1 (ja) |
JP (1) | JP4382163B2 (ja) |
AT (1) | ATE417112T1 (ja) |
CA (1) | CA2285692C (ja) |
DE (1) | DE69840326D1 (ja) |
NZ (1) | NZ500151A (ja) |
WO (1) | WO1998044129A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014534807A (ja) * | 2011-09-23 | 2014-12-25 | ユニバーシティ オブ オスロUniversity of Oslo | クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2003516147A (ja) * | 1999-12-10 | 2003-05-13 | アリアド ジーン セラピューティクス インコーポレイテッド | 霊長類における高レベルの遺伝子発現方法 |
US7786257B2 (en) * | 2000-12-18 | 2010-08-31 | University Of Kansas | Signal-1/signal-2 bifunctional peptide inhibitors |
AUPR524101A0 (en) | 2001-05-25 | 2001-06-21 | Council Of The Queensland Institute Of Medical Research, The | Antigen targeting |
AU2002256565B2 (en) * | 2001-05-25 | 2007-07-12 | The Council Of The Queensland Institute Of Medical Research | Antigen targeting |
GB0113798D0 (en) | 2001-06-06 | 2001-07-25 | Chiron Spa | Antigens and vectors for vaccination |
EP1633372B1 (en) * | 2003-06-13 | 2011-11-30 | The Trustees of The University of Pennsylvania | Vaccines, immunotherapeutics and methods for using the same |
US20050137156A1 (en) * | 2003-08-09 | 2005-06-23 | Johnston Stephen A. | Methods and compositions for generating an immune response |
ES2304812B1 (es) * | 2003-12-03 | 2009-10-21 | Instituto Nacional De Investigacion Y Tecnologia Agraria Y Alimentaria (Inia) | Sistema para producir peptidos y proteinas, multimericos, y sus aplicaciones. |
AU2004235659B2 (en) * | 2004-12-06 | 2011-08-18 | The Council Of The Queensland Institute Of Medical Research | Relay Vaccine |
WO2019008001A1 (en) * | 2017-07-04 | 2019-01-10 | Curevac Ag | NEW NUCLEIC ACID MOLECULES |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5637481A (en) * | 1993-02-01 | 1997-06-10 | Bristol-Myers Squibb Company | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
AU661854B2 (en) * | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
US6719972B1 (en) * | 1994-06-03 | 2004-04-13 | Repligen Corporation | Methods of inhibiting T cell proliferation or IL-2 accumulation with CTLA4- specific antibodies |
US5698679A (en) * | 1994-09-19 | 1997-12-16 | National Jewish Center For Immunology And Respiratory Medicine | Product and process for targeting an immune response |
WO1996040941A1 (en) * | 1995-06-07 | 1996-12-19 | Connaught Laboratories Limited | Chimeric antibodies for delivery of antigens to selected cells of the immune system |
US6080409A (en) * | 1995-12-28 | 2000-06-27 | Dendreon Corporation | Immunostimulatory method |
US6224870B1 (en) * | 1997-01-24 | 2001-05-01 | Genitrix, Ltd. | Vaccine compositions and methods of modulating immune responses |
AU3804397A (en) * | 1996-06-14 | 1998-01-07 | Smithkline Beecham Corporation | Hexameric fusion proteins and uses therefor |
-
1998
- 1998-03-26 CA CA2285692A patent/CA2285692C/en not_active Expired - Lifetime
- 1998-03-26 WO PCT/AU1998/000208 patent/WO1998044129A1/en active IP Right Grant
- 1998-03-26 JP JP54098998A patent/JP4382163B2/ja not_active Expired - Lifetime
- 1998-03-26 AT AT98910530T patent/ATE417112T1/de not_active IP Right Cessation
- 1998-03-26 DE DE69840326T patent/DE69840326D1/de not_active Expired - Lifetime
- 1998-03-26 NZ NZ500151A patent/NZ500151A/xx not_active IP Right Cessation
- 1998-03-26 EP EP98910530A patent/EP0972054B1/en not_active Expired - Lifetime
-
2002
- 2002-06-28 US US10/185,318 patent/US7423016B2/en not_active Expired - Fee Related
- 2002-06-28 US US10/185,799 patent/US7423023B2/en not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2014534807A (ja) * | 2011-09-23 | 2014-12-25 | ユニバーシティ オブ オスロUniversity of Oslo | クロスプレゼンテーションを行う樹状細胞を標的としたワクチボディ |
Also Published As
Publication number | Publication date |
---|---|
US20030035793A1 (en) | 2003-02-20 |
US7423023B2 (en) | 2008-09-09 |
WO1998044129A1 (en) | 1998-10-08 |
US7423016B2 (en) | 2008-09-09 |
CA2285692C (en) | 2013-05-28 |
EP0972054B1 (en) | 2008-12-10 |
NZ500151A (en) | 2001-01-26 |
EP0972054A4 (en) | 2005-02-23 |
ATE417112T1 (de) | 2008-12-15 |
US20030072742A1 (en) | 2003-04-17 |
EP0972054A1 (en) | 2000-01-19 |
CA2285692A1 (en) | 1998-10-08 |
DE69840326D1 (de) | 2009-01-22 |
JP4382163B2 (ja) | 2009-12-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5942296B2 (ja) | 少なくとも1つのcxxcモチーフを含むポリペプチドと異種抗原とを含む医薬組成物、及びその使用 | |
KR101998431B1 (ko) | 리포솜 제제 | |
US20090004194A1 (en) | Tlr agonist (flagellin)/cd40 agonist/antigen protein and dna conjugates and use thereof for inducing synergistic enhancement in immunity | |
JP6874031B2 (ja) | アイメリアに対する免疫応答を強化するか又はアイメリア感染症を制限する組成物及び方法 | |
CN1942205B (zh) | 可经粘膜和经皮给予的抗原药物媒介物、使用该媒介物的粘膜免疫的诱导方法、粘膜疫苗和dds | |
JP2003505431A (ja) | タンパク質抗原およびペプチド抗原の免疫原性を増強するためのfc融合タンパク質 | |
AU2011207331C1 (en) | Vaccine vectors and methods of enhancing immune responses | |
TW202039587A (zh) | 供合成胜肽免疫原作為免疫刺激劑的人工混雜t輔助細胞抗原決定位 | |
JP2001522235A (ja) | ターゲッティング分子を用いた免疫応答の増強 | |
JP2005528373A (ja) | 免疫プロトコルにFlt3リガンドを用いる方法 | |
US9119803B2 (en) | Carious tooth vaccine and preparation method | |
JP5901084B2 (ja) | ペプチドアジュバント | |
JP7239203B2 (ja) | IgE媒介型アレルギー性疾患治療のための、膜結合型IgEを標的とするペプチド免疫原及びそれらの製剤 | |
JP7045024B2 (ja) | マラリアワクチン | |
US10183067B1 (en) | TAA/CD4OL composition/vaccine for malaria | |
WO2018088509A1 (ja) | マラリアワクチン | |
JP2001151698A (ja) | インフルエンザワクチン | |
JP2003535147A (ja) | 遊離形態でfhaタンパク質又はそのフラグメントを含むアジュバント組成物 | |
WO2018085488A1 (en) | Universal mammalian influenza vaccine | |
WO2023020637A1 (es) | Antigenos quimericos para el control de coronavirus y composiciones que los comprenden | |
JP2003277292A (ja) | マラリア原虫伝搬阻止粘膜ワクチン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050318 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070828 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20071122 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20080111 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20090714 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20090825 |
|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20090917 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121002 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131002 Year of fee payment: 4 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |